Interestingly, several BET inhibitors are on clinical trials targeting many cancer types, including the compounds OTX015 and GSK525762 for NUT midline carcinoma, acute myeloid leukemia and myelodysplastic syndrome (NCT02308761), and lymphoma (NCT01949883) and multiple myeloma (NCT02157636) [22]. This evidence concerns the gene DNER and plasma cell myeloma.